Perosphere and Daiichi Sankyo have agreed to work together on a clinical trial that will assess the efficacy and safety of PER977, a drug being designed to reverse the anticoagulant effect of edoxaban, a factor Xa inhibitor. In preclinical testing, PER977 attached to heparins and factor Xa and IIa inhibitors but not to blood proteins.